Patents Examined by Ellen J Marcsisin
  • Patent number: 10955413
    Abstract: An object of the present invention is to provide means for correctly measuring zygomycota. The present inventors have found that conventionally difficult zygomycota measurement can be performed through subjecting an untreated specimen to an acid treatment. The present invention provides a method for measuring zygomycota, the method including measuring zygomycota in a specimen that was subjected to an acid treatment; an agent for preparing a specimen for measurement of zygomycota; a method for preparing a specimen for measurement of zygomycota; and a reagent kit for measuring zygomycota.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Maki Aizawa, Koichi Makimura
  • Patent number: 10942175
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 9, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Huedig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 10935557
    Abstract: Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 2, 2021
    Assignee: FUTURE DIAGNOSTICS B.V.
    Inventors: Michaƫl Franciscus Wilhelmus Cornelis Martens, George Henry Parsons, Franciscus Maria Anna Rosmalen, Leon Maria Jacobus Wilhelmus Swinkels
  • Patent number: 10890590
    Abstract: Apparatus is disclosed for identifying at least a first target condition in a human or animal body. The apparatus comprises one or more test portions for identifying a first analyte in a biological sample from the body, the first analyte providing a marker of the first target condition, and a second analyte in the biological sample, the second analyte being different from the first analyte. The apparatus is configured to identify the first target condition in the body based on the identification of both the first and second analytes. In one embodiment, the first target condition is pregnancy, the first analyte is human chorionic gonadotropin (hCG) and the second analyte is luteinizing hormone (LH).
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 12, 2021
    Assignee: Ellume Limited
    Inventor: Sean Andrew Parsons
  • Patent number: 10882900
    Abstract: The present invention provides a monoclonal antibody that specifically binds to human-derived procalcitonin and application thereof. The present invention also provides a hybridoma cell line secreting the monoclonal antibody and having an accession number of CGMCC No. 10417, and a method for preparing an antibody against procalcitonin by using a procalcitonin mutant antigen as the immunogen.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: January 5, 2021
    Assignee: Nanjing Norman Biological Technology Co., Ltd.
    Inventors: Sen Ye, Shizhao He
  • Patent number: 10794906
    Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 6, 2020
    Assignee: Prometheus Biosciences, Inc.
    Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
  • Patent number: 10794801
    Abstract: An object of the present invention is, in the case when a specific substance that has expressed on cells to be detected in a liquid sample is to be specifically stained, to provide a convenient cell staining method by which the damage and loss (flow out) of the cells in the collected sample are prevented, and the time has been shortened in a procedure for staining the cells in the liquid sample. Furthermore, another object of the present invention is to provide a sample collection tube that is suitable for use in the above-mentioned cell staining method. A method for specifically staining a specific substance possessed by cells in a sample, including performing the following steps in one step: (A) a step of performing an immobilization treatment of the cells; and (B) a step of performing a permeabilization treatment of the cells.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 6, 2020
    Assignee: KONICA MINOLTA, INC.
    Inventors: Tsuneko Chiyoda, Jungo Araki
  • Patent number: 10794917
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in appendicitis patients and in patients at risk for appendicitis. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: October 6, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf, Thomas Kwan
  • Patent number: 10788489
    Abstract: The present invention relates to a method for the detection of a protein including a histidine-tag using immunochromatography. The detection method of the present invention uses immunochromatography using the polymer particle fixed with the histidine-tag, wherein a histidine-tag specific antibody alone is used to detect a histidine-tag conjugated protein (recombinant protein) quickly without using a target protein specific antibody. This method is also efficient in detecting and quantifying the histidine-tagged protein included in the sample without using an additional apparatus but quickly and accurately.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: September 29, 2020
    Assignee: Daegu Gyeongbuk Institute of Science and Technology
    Inventors: Eun Joo Kim, Won Bae Jeon, Sung Jun Lee, Se Geun Lee, Eun Sook Choi
  • Patent number: 10627408
    Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 21, 2020
    Assignee: Cyrex Laboratories, LLC
    Inventor: Aristo Vojdani
  • Patent number: 10585095
    Abstract: Disclosed herein are systems, methods, and devices for monitoring and controlling bioprocess parameters. The systems and methods enable automated operation with real-time analysis of process conditions and analyte or biologic production.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: March 10, 2020
    Inventor: Andrew Sulya
  • Patent number: 10571396
    Abstract: The present invention is directed to multiplexed fluorescence detection, including time-resolved fluorescence (TRF) detection. A combination of spectral and temporal differences in fluorescence emission and spectral differences in excitation is used to enhance the ability to separate signals in an assay from multiple fluorescent labels. Different classes of labels may be utilized, including upconversion phosphors as well as lanthanide chelates and transition metal chelates. The methods may be implemented in optical plate readers, including cartridge-based multi-mode readers.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: February 25, 2020
    Assignee: Molecular Devices, LLC
    Inventors: Annegret Schramm, Michael Katzlinger
  • Patent number: 10571371
    Abstract: The disclosure provides improved materials and methods for optically clearing biological tissue that is subsequently used for deep tissue imaging analysis. Also provided is a description of a microscopic image acquisition methodology in which imagery of intact tissues are acquired to rapidly acquire microscopy data on a whole-organ scale to maximize cost effectiveness for biological microscopy and minimize time spent performing such analysis.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: February 25, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Frank Marini, George Christ
  • Patent number: 10551386
    Abstract: The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of a part stained for morphological observation when the fluorescent label used for the immunostaining is observed.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: February 4, 2020
    Assignee: KONICA MINOLTA, INC.
    Inventors: Kensaku Takanashi, Hisatake Okada, Yasushi Nakano, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe
  • Patent number: 10527526
    Abstract: Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: January 7, 2020
    Assignee: Tripath Imaging, Inc.
    Inventors: Timothy J. Fischer, Ramona R. Nelson, Adriann J. Taylor, Clark M. Whitehead
  • Patent number: 10527620
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • Patent number: 10495652
    Abstract: Advantage is taken of macrolide antibiotics' complexation with free cholesterol to yield fluorescent complexes to determine the levels of free cholesterol, total cholesterol, or lecithin: cholesterol acyl transferase (LCAT) in serum or plasma or fractions thereof.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 3, 2019
    Assignee: Roar Holding LLC
    Inventor: Robert W. Brocia
  • Patent number: 10472400
    Abstract: A cardiac troponin I ultra-sensitive detection reagent kit, a preparation method, and a detection method. The reagent kit comprises at least one first anti-cardiac troponin I antibody marked with a trace marker and at least one second anti-cardiac troponin I antibody coated on magnetic microspheres, the first anti-cardiac troponin I antibody and cardiac troponin I binding site being different from the second anti-cardiac troponin I antibody and cardiac troponin I binding site. The reagent kit may further comprise a diluent capable of significantly reducing non-specific binding in a detection process, so as to further increase the detection accuracy and sensitivity. The method using the reagent kit to detect cardiac troponin I sensitively and accurately detects the amount of cardiac troponin I in a sample, and provides more timely and reliable information for the early diagnosis and treatment of AMI.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: November 12, 2019
    Assignee: SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD
    Inventors: Wei Rao, Jinyun Yuan, Qin Li, Sheng Wang, Hong Xu, Wu Li, Tinghua Li, Jinqiu Fu
  • Patent number: 10451635
    Abstract: The present invention relates to a beef-specific age determination marker containing the p21 protein, to an antibody specifically bound to bovine p21 protein, to a beef-specific age determination kit containing the antibody which is specifically bound to the bovine p21 protein, and to a method which involves detecting the bovine p21 protein through an antigen-antibody binding reaction using the antibody which is specifically bound to the bovine p21 protein serving as a beef-specific age determination marker in the muscle tissue of beef, so as to determine the age of the beef. According to the present invention, the p21 protein is significantly greatly expressed in the muscle tissue of beef, the age of which is lower than 30 months, and is hardly expressed in the muscle tissue of beef, the age of which is greater than 30 months, and thus can be valuably used as a beef-specific age determination marker.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: October 22, 2019
    Assignee: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Ik Soon Jang, Jong Soon Choi, Joseph Kwon, Dong-Gi Lee, Kyeong Eun Yang
  • Patent number: 10422797
    Abstract: An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: September 24, 2019
    Assignees: ROCHE DIAGNOSTICS OPERATIONS, INC., HITACHI HIGH-TECHNOLOGIES CORPORATION
    Inventors: Ralf Kraus, Oliver Larbolette, Friedrich Staebler, Yoshihiro Yamashita, Yukinori Sakashita, Shinya Matsuoka, Michihiro Saito, Taku Sakazume, Katsuaki Takahashi